| Dr Michael Self, MD | |
|
200 W Arbor Dr, Mc8676, San Diego, CA 92103-9000 | |
| (619) 543-4627 | |
| (619) 543-3115 |
| Full Name | Dr Michael Self |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 7 Years |
| Location | 200 W Arbor Dr, San Diego, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053702746 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A158182 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Uc San Diego Health Hillcrest - Hillcrest Med Ctr | San diego, CA | Hospital |
| El Centro Regional Medical Center | El centro, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Regents Of The University Of California | 3577476761 | 1692 |
| Regents Of The University Of California | 6406760131 | 34 |
News Archive
Dr. Andrew Gewirtz, a professor in the Institute for Biomedical Sciences at Georgia State University, has received a four-year federal grant just over $2 million to study how inflammation and altered gut microbiota, the microorganisms living in the intestine, influence the development of a group of diseases referred to as metabolic syndrome.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn's disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.
"Arkansas Sen. Blanche Lincoln has run two successful Senate campaigns on pledges to expand and improve health insurance coverage. Now, as Congress works to deliver on that promise, it threatens to become an issue that could end her career."
Medicaid Health Plans of America, the leading trade association solely focused on representing Medicaid health plans, responded today to an annual report just released by the Centers for Medicare and Medicaid Services on Medicaid managed care enrollment, which showed Medicaid health plan enrollment grew by almost 2.4 million members in 2009 to more than 23.4 million Americans nationwide.
A rare plant found only at two sites in central Wyoming has persisted, in part, because it can recover from relatively low densities and grows at different rates within each location, according to new research led by a University of Wyoming scientist.
› Verified 9 days ago
| Entity Name | Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780870899 PECOS PAC ID: 6406760131 Enrollment ID: O20031117000940 |
News Archive
Dr. Andrew Gewirtz, a professor in the Institute for Biomedical Sciences at Georgia State University, has received a four-year federal grant just over $2 million to study how inflammation and altered gut microbiota, the microorganisms living in the intestine, influence the development of a group of diseases referred to as metabolic syndrome.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn's disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.
"Arkansas Sen. Blanche Lincoln has run two successful Senate campaigns on pledges to expand and improve health insurance coverage. Now, as Congress works to deliver on that promise, it threatens to become an issue that could end her career."
Medicaid Health Plans of America, the leading trade association solely focused on representing Medicaid health plans, responded today to an annual report just released by the Centers for Medicare and Medicaid Services on Medicaid managed care enrollment, which showed Medicaid health plan enrollment grew by almost 2.4 million members in 2009 to more than 23.4 million Americans nationwide.
A rare plant found only at two sites in central Wyoming has persisted, in part, because it can recover from relatively low densities and grows at different rates within each location, according to new research led by a University of Wyoming scientist.
› Verified 9 days ago
| Entity Name | Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578672184 PECOS PAC ID: 3577476761 Enrollment ID: O20031211000464 |
News Archive
Dr. Andrew Gewirtz, a professor in the Institute for Biomedical Sciences at Georgia State University, has received a four-year federal grant just over $2 million to study how inflammation and altered gut microbiota, the microorganisms living in the intestine, influence the development of a group of diseases referred to as metabolic syndrome.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn's disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.
"Arkansas Sen. Blanche Lincoln has run two successful Senate campaigns on pledges to expand and improve health insurance coverage. Now, as Congress works to deliver on that promise, it threatens to become an issue that could end her career."
Medicaid Health Plans of America, the leading trade association solely focused on representing Medicaid health plans, responded today to an annual report just released by the Centers for Medicare and Medicaid Services on Medicaid managed care enrollment, which showed Medicaid health plan enrollment grew by almost 2.4 million members in 2009 to more than 23.4 million Americans nationwide.
A rare plant found only at two sites in central Wyoming has persisted, in part, because it can recover from relatively low densities and grows at different rates within each location, according to new research led by a University of Wyoming scientist.
› Verified 9 days ago
| Entity Name | Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356444897 PECOS PAC ID: 3577476761 Enrollment ID: O20040109000444 |
News Archive
Dr. Andrew Gewirtz, a professor in the Institute for Biomedical Sciences at Georgia State University, has received a four-year federal grant just over $2 million to study how inflammation and altered gut microbiota, the microorganisms living in the intestine, influence the development of a group of diseases referred to as metabolic syndrome.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn's disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.
"Arkansas Sen. Blanche Lincoln has run two successful Senate campaigns on pledges to expand and improve health insurance coverage. Now, as Congress works to deliver on that promise, it threatens to become an issue that could end her career."
Medicaid Health Plans of America, the leading trade association solely focused on representing Medicaid health plans, responded today to an annual report just released by the Centers for Medicare and Medicaid Services on Medicaid managed care enrollment, which showed Medicaid health plan enrollment grew by almost 2.4 million members in 2009 to more than 23.4 million Americans nationwide.
A rare plant found only at two sites in central Wyoming has persisted, in part, because it can recover from relatively low densities and grows at different rates within each location, according to new research led by a University of Wyoming scientist.
› Verified 9 days ago
| Entity Name | Uc San Diego Health Community Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659864247 PECOS PAC ID: 3971849175 Enrollment ID: O20190109000943 |
News Archive
Dr. Andrew Gewirtz, a professor in the Institute for Biomedical Sciences at Georgia State University, has received a four-year federal grant just over $2 million to study how inflammation and altered gut microbiota, the microorganisms living in the intestine, influence the development of a group of diseases referred to as metabolic syndrome.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn's disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.
"Arkansas Sen. Blanche Lincoln has run two successful Senate campaigns on pledges to expand and improve health insurance coverage. Now, as Congress works to deliver on that promise, it threatens to become an issue that could end her career."
Medicaid Health Plans of America, the leading trade association solely focused on representing Medicaid health plans, responded today to an annual report just released by the Centers for Medicare and Medicaid Services on Medicaid managed care enrollment, which showed Medicaid health plan enrollment grew by almost 2.4 million members in 2009 to more than 23.4 million Americans nationwide.
A rare plant found only at two sites in central Wyoming has persisted, in part, because it can recover from relatively low densities and grows at different rates within each location, according to new research led by a University of Wyoming scientist.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Self, MD Po Box 232410, San Diego, CA 92193-2410 Ph: (800) 926-8273 | Dr Michael Self, MD 200 W Arbor Dr, Mc8676, San Diego, CA 92103-9000 Ph: (619) 543-4627 |
News Archive
Dr. Andrew Gewirtz, a professor in the Institute for Biomedical Sciences at Georgia State University, has received a four-year federal grant just over $2 million to study how inflammation and altered gut microbiota, the microorganisms living in the intestine, influence the development of a group of diseases referred to as metabolic syndrome.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn's disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.
"Arkansas Sen. Blanche Lincoln has run two successful Senate campaigns on pledges to expand and improve health insurance coverage. Now, as Congress works to deliver on that promise, it threatens to become an issue that could end her career."
Medicaid Health Plans of America, the leading trade association solely focused on representing Medicaid health plans, responded today to an annual report just released by the Centers for Medicare and Medicaid Services on Medicaid managed care enrollment, which showed Medicaid health plan enrollment grew by almost 2.4 million members in 2009 to more than 23.4 million Americans nationwide.
A rare plant found only at two sites in central Wyoming has persisted, in part, because it can recover from relatively low densities and grows at different rates within each location, according to new research led by a University of Wyoming scientist.
› Verified 9 days ago
Sarah Wilkinson, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 W Arbor Dr # 8819, San Diego, CA 92103 Phone: 956-458-9885 | |
Dr. Ramandeep Singh Dhillon, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5454 El Cajon Blvd, San Diego, CA 92115 Phone: 619-515-2400 | |
Mina Kyrollus Ghobrial, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 200 W Arbor Dr, San Diego, CA 92103 Phone: 800-926-8273 Fax: 888-539-8781 | |
Dr. Timothy Stuart Hinman, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2001 4th Ave, San Diego, CA 92101 Phone: 858-499-2600 | |
Dr. Peter D. Aldrich, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 15025 Innovation Dr, San Diego, CA 92128 Phone: 858-554-8638 | |
Dr. Matthew J. Perl, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 15004 Innovation Dr, San Diego, CA 92128 Phone: 858-605-7171 | |
Jeffrey Adam Bush, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 4647 Zion Ave, San Diego, CA 92120 Phone: 619-528-5000 |